Cantabio Pharmaceuticals Inc. Stock Price - CTBO

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Cantabio Pharmaceuticals Inc. CTBO Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 0.005 0.00 0.00 0.00 0.005 20:00:00
Bid Price Ask Price Spread Spread % News
0.003 0.005 0.002 40.00% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Cantabio Pharmaceuticals Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 563.62k 112.72M $ -2.01M - -0.28 20.4M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cantabio Pharmaceuticals Inc. News

Latest CTBO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTBO Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.004990.0060.00280.004950k1M578k0.000010.20%
1 Month0.0050.007550.00280.00515701M101k0-
3 Months0.00350.0170.00250.00473201M169k0.001542.86%
6 Months0.0060.0170.00210.00501003M234k-0.001-16.67%
1 Year0.02960.04880.00210.00941003M175k-0.0246-83.11%
3 Years2.063.270.00210.2115103M90k-2.055-99.76%
5 Years33.790.00210.3102103M90k-2.995-99.83%

Cantabio Pharmaceuticals Inc. Description

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson's disease (PD), Alzheimer's disease (AD) and other related neurodegenerative diseases. Our strategy integrates therapeutic focus, target family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.


Your Recent History
USOTC
CTBO
Cantabio P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.